title: Improving results of pediatric renal transplantation.
abstract: BACKGROUND
  Outcome after renal transplantation in children has been variable. We undertook a retrospective study of our experience over the past five years.
  
  
  METHODS
  From January 1, 1988, to October 15, 1992, 60 renal transplantations were performed upon 59 children at the Children's Hospital of Pittsburgh. Twenty-eight (47 percent) of the kidneys were from cadaveric donors, and 32 (53 percent) were from living donors. The recipients ranged in age from 0.8 to 17.4 years, with a mean of 9.8 +/- 4.8 years. Forty-six (77 percent) recipients were undergoing a first transplant, while 14 (23 percent) received a second or third transplant. Eight (13 percent) of the patients were sensitized, with a panel reactive antibody of more than 40 percent. Eleven of the 14 patients undergoing retransplantation and seven of the eight patients who were sensitized received kidneys from cadaveric donors. Thirty-three (55 percent) patients received cyclosporine-based immunosuppression, and 27 (45 percent) received FK506 as the primary immunosuppressive agent.
  
  
  RESULTS
  The median follow-up period was 36 months, with a range of six to 63 months. The one- and four-year actuarial patient survival rate was 100 and 98 percent. The one- and four-year actuarial graft survival rate was 98 and 83 percent. For living donor recipients, the one- and four-year actuarial patient survival rate was 100 and 100 percent; for cadaveric recipients, it was 100 and 96 percent. Corresponding one- and four-year actuarial graft survival rates were 100 and 95 percent for the living donor recipients and 96 and 69 percent for the cadaveric recipients. Patients on cyclosporine had a one- and four-year patient survival rate of 100 and 97 percent, and patients on FK506 had a one- and three-year patient survival rate of 100 and 100 percent. Corresponding one- and four-year actuarial graft survival rates were 100 and 85 percent in the cyclosporine group, while one- and three-year actuarial graft survival rates were 96 and 84 percent in the FK506 group. The mean serum creatinine level was 1.24 +/- 0.64 mg per dL; the blood urea nitrogen level was 26 +/- 13 mg per dL. The incidence of rejection was 47 percent; 75 percent of the rejections were steroid-responsive. The incidence of cytomegalovirus was 10 percent. The incidence of post-transplant lymphoproliferative disorder was 8 percent. None of the patients on cyclosporine were able to be taken off prednisone; 56 percent of the patients receiving FK506 were taken off prednisone successfully. Early growth and development data suggest that the patients receiving FK506 off prednisone had significant gains in growth.
  
  
  CONCLUSIONS
  These results support the idea that renal transplantation is a successful therapy for end-stage renal disease in children. They also illustrate the potential benefits of a new immunosuppressive agent, FK506.
authors.affiliation: Pittsburgh Transplantation Institute, Department of Surgery, University of Pittsburgh Health Science Center, PA.
authors.forename: R
authors.initials: R
authors.lastname: Shapiro
authors.forename: A
authors.initials: A
authors.lastname: Tzakis
authors.forename: V
authors.initials: V
authors.lastname: Scantlebury
authors.forename: M
authors.initials: M
authors.lastname: Jordan
authors.forename: C
authors.initials: C
authors.lastname: Vivas
authors.forename: D
authors.initials: D
authors.lastname: Ellis
authors.forename: N
authors.initials: N
authors.lastname: Gilboa
authors.forename: W
authors.initials: W
authors.lastname: Irish
authors.forename: L
authors.initials: L
authors.lastname: Hopp
authors.forename: J
authors.initials: J
authors.lastname: Reyes
mesh_terms: D000293:Adolescent; D002648:Child; D002675:Child, Preschool; D006801:Humans; D007165:Immunosuppression Therapy / Q000379:methods; D007223:Infant; D007676:Kidney Failure, Chronic / Q000209:etiology / Q000503:physiopathology; D016030:Kidney Transplantation; D011183:Postoperative Complications; D012189:Retrospective Studies; D016019:Survival Analysis; D016559:Tacrolimus / Q000627:therapeutic use; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D016559:Tacrolimus